Vistagen Therapeutics Inc
(VTGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 694 | 121 | 70 | 13 | N/A |
| TOTAL | $1,797 | $1,594 | $106 | $76 | $190 |
| Non-Current Assets | |||||
| PPE Net | 88 | 103 | 117 | 137 | 150 |
| Other Non-Current Assets | 47 | 47 | 47 | 47 | 47 |
| TOTAL | $135 | $150 | $164 | $184 | $197 |
| Total Assets | $1,933 | $1,744 | $270 | $259 | $387 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 8,304 | 4,882 | 1,563 |
| Accounts payable and accrued liabilities | 1,110 | 1,550 | 2,251 | 2,415 | 2,248 |
| Accrued Expenses | 1,131 | 1,382 | 1,207 | 1,193 | 857 |
| TOTAL | $2,349 | $3,279 | $17,388 | $10,764 | $6,894 |
| Non-Current Liabilities | |||||
| Long Term Debt | 31 | 1,039 | 36 | 3,254 | 3,145 |
| Other Non-Current Liabilities | 805 | 213 | 3,305 | 3,936 | 7,624 |
| TOTAL | $909 | $1,331 | $3,424 | $7,279 | $10,863 |
| Total Liabilities | $3,257 | $4,610 | $20,813 | $18,043 | $17,756 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 58 | 53 | 53 | 49 | 43 |
| Common Shares | 2 | 2 | 2 | 1 | 1 |
| Retained earnings | -121,095 | -114,047 | -84,523 | -78,301 | -77,211 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | -161 |
| TOTAL | $-1,325 | $-2,866 | $-20,543 | $-17,783 | $-17,369 |
| Total Liabilities And Equity | $1,933 | $1,744 | $270 | $259 | $387 |